Sofinnova Venture Partners X, L.P. - Jan 6, 2022 Form 3 Insider Report for CinCor Pharma, Inc. (CINC)

Role: 10%+ Owner
Signature: Sofinnova Venture Partners X, L.P., By: Sofinnova Management X, L.L.C. , its general partner, By /s/ Maha Katabi, Managing Member
Stock symbol: CINC
Transactions as of: Jan 6, 2022
Transactions value $: $0
Form type: 3
Date filed: 1/6/2022, 07:54 PM
Previous filing: Jul 6, 2021
Next filing: Jan 13, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CINC	Series A Preferred Stock							Jan 6, 2022	Common Stock	3.99M		By Sofinnova Venture Partners X, L.P.	F1, F2
holding	CINC	Series B Preferred Stock							Jan 6, 2022	Common Stock	1.26M		By Sofinnova Venture Partners X, L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of Common Stock on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
F2	The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports.

Content

Each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of Common Stock on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports.